US Stem Cell Inc (USRM)

[Dragon Lady]

Vast and vague "programs" and incredible "claims" even in 2008/2009- what happened to all of them? Where are they today?

Seems like a lot of the "stuff" on that list form 2008, is still being regurgitated today in one form or another IMO. It's just re-playing the same old variations on the same song to me.

http://www.bloomberg.com/apps/news?pid=newsarchive&sid=ajkzX9o9TTDY

Remember the ole TGI-1200 system??

http://www.ascrnetwork.com/index.php?option=com_content&view=article&id=1695:bioheart-reports-promising-results-from-preclinical-study-of-adipose-derived-acute-cell-therapy282&catid=91

http://www.drugs.com/clinical_trials/bioheart-reports-promising-results-preclinical-study-adipose-derived-acute-cell-therapy-5596.html

http://www.biospace.com/News/bioheart-inc-strengthens-executive-team-in-order/153495

That was the ole "strengthen the team" PR and a lot of Myocell SDF-1 "claims" even way, way back then- all like today IMO. What ever happened to um?

http://globenewswire.com/news-release/2009/05/07/397137/164884/en/Bioheart-Reports-Year-End-2008-Results-Reviews-2008-and-1Q09-Progress-and-2009-Business-Objectives.html?print=1

That one's a classic IMO. Read this wash list of items "projected" to happen clear back in 2009 (the yr they were delisted from the NASDAQ). They "projected" a "run rate" aka SALES of $22 MA MILLION dollars from some "product" that I don't think even ever sold- and sure is never spoken about today as far as I know?? Just vast "claims" and "projects"- vague and broad IMO, like a good "conference call", you know?

QUOTE from the 2009 "news PR link" above:Bioheart's business objectives for 2009 and beyond include the following:

* Reach Bioheart 3370 Heart Failure Monitoring Systems sales of an
annual run rate of $22 million. FDA 510(k), European CE Mark and
Reimbursement already in place.
* Complete interim analysis of MARVEL Study patients.
* Expand global distribution network in Europe and Asia-Pacific and
related sales pact.
* Move MyoCell(r) SDF-1 second-generation composition for advanced
heart failure into Phase II/III pivotal clinical trial.
* Launch U.S. 510(k) authorized Bioheart-Monebo Cardiobelt(r) in U.S.
market.
* Keep operating loss for year to under $5.4 million.
* Publish in peer reviewed journals Phase II SEISMIC and MYOHEART U.S.
Dose Escalation Study Results.
* Gain reimbursement approval for MyoCell in Europe for treating
sickest heart failure patients.
* Launch sales of CE Mark approved Bioheart A&C Bio Science T-PLS(r)
Twin-Pulsatile Life Support System system in Europe.
* Finish development with corporate partner of implantable heart
failure sensor that communicates wirelessly with the Bioheart 3370
Heart Failure Monitoring System.
* Finish development of implantable heart pump on percutaneous
catheter with corporate partner in Korea, A&C Bio Science, Inc.
* Sell off rights to non-core intellectual property and product
developments to increase cash available for core heart failure
focused developments: AortaCell, MyoStim, MyoValve, BioPace,
EndoCell, and MyoCath.
* Seek joint venture partner to commercially develop the A&C Bio
Science LVAD/SVAD, a significantly lower-cost left ventricle assist
device co-developed by Bioheart.
* Continue to add devices to product lineup that feed information
into the Bioheart 3370 24-hour monitoring system.

"

End quote.

Greeeaaaat sounding ole "stuff" eh? How much if ANY of it ever actually happened or even remotely came true? How much?

So how much of that wash list ever actually happened to came true? And they had how much cash back then and how many employees and all? A whole lot more than today- that's for sure.

So now some of that "stuff" is being supposedly re-birthed today when they have 4 full time employees total and little to no cash? MARVEL- see how it was all being "talked up" even clear back then, in a 2009 big PR?

It's all the same to me- I don't see what is "exciting" or "going to move the price" or "cause the market cap to increase" or was "great" and all the rest about some "conference call"?? Makes no sense to me personally- I've seen and heard so much of it from BHRT so many times in the past.

Here, here's a few more GREAT "sounding" one from not too long ago. I mean "sounded" GREAT (term sheets, and we think, and 3 maybe partners just like that 2009 PR had "partners" plastered all over it", and we're "working with" and blah, blah, blah, same old IMO, all the same to me)

http://www.marketwired.com/press-release/northstar-launches-20-million-private-placement-round-with-proceeds-fund-bioheart-trials-otcqb-bhrt-1713163.htm

http://www.marketwired.com/press-release/bioheart-receives-2-million-term-sheet-investment-offer-from-vitalmex-global-leader-otcbb-bhrt-1686526.htm

http://www.bizjournals.com/southflorida/news/2011/04/26/bioheart-terminates-anc-bio-investment.html

http://www.bloomberg.com/apps/news?pid=newsarchive&sid=asecNvIZ.xXI

http://globenewswire.com/news-release/2012/02/29/469402/247547/en/Bioheart-Appoints-Advisory-Board-of-Business-and-Financial-Executives.html?print=1

http://globenewswire.com/news-release/2012/01/30/466536/244075/en/Frank-Young-Joins-Bioheart-as-Financial-Consultant.html

http://www.heartbeatineurope.org/de/news_center/34.html?newsID=186